|
🐢
|
Long-term use of antimalarial drugs in rheumatic diseases.
10 auth.
J. Jover,
L. León,
E. Pato,
Estíbaliz Loza,
Z. Rosales,
Matias Ma,
...
R. Méndez-Fernández,
D. Díaz-Valle,
J. Benítez-del-Castillo,
L. Abasolo
|
5 |
2012 |
5
🐢
|
|
🐢
|
Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice
8 auth.
L. León,
L. Rodríguez-Rodríguez,
Z. Rosales,
A. Gómez,
J. Lamas,
E. Pato,
...
J. Jover,
L. Abasolo
|
5 |
2016 |
5
🐢
|
|
🐢
|
THU0309 Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice
11 auth.
L. León,
L. Rodríguez-Rodríguez,
I. Morado,
Z. Rosales,
C. Vadillo,
D. Freites,
...
P. Macarrón,
B. Fernández-Gutiérrez,
M. Blanco,
J. Jover,
L. Abasolo
|
4 |
2017 |
4
🐢
|
|
🐜
|
[Incidence and characteristics of tuberculosis in patients with autoimmune rheumatic diseases].
10 auth.
C. VadilloFont,
C. Hernández-García,
E. Pato,
I. Morado,
M. Salido,
E. Júdez,
...
P. Macarrón,
B. Fernández-Gutiérrez,
L. Abasolo,
J. Jover
|
4 |
2003 |
4
🐜
|
|
🐢
|
Hospital admissions in inflammatory rheumatic diseases during the COVID-19 pandemic: incidence and role of disease modifying agents
10 auth.
B. Fernández-Gutiérrez,
L. León,
A. Madrid,
L. Rodríguez-Rodríguez,
D. Freites,
J. Font,
...
A. Mucientes,
J. I. Colomer,
J. Jover,
L. Abasolo
|
4 |
2020 |
4
🐢
|
|
🐢
|
Persistent post-discharge symptoms after COVID-19 in rheumatic and musculoskeletal diseases
11 auth.
L. León,
I. Pérez-Sancristóbal,
A. Madrid,
Leticia Lopez-Pedraza,
J. I. Colomer,
S. Lerma,
...
P. Lois,
A. Mucientes,
L. Rodríguez-Rodríguez,
B. Fernández-Gutiérrez,
L. Abasolo
|
3 |
2022 |
3
🐢
|
|
🐢
|
Risk factors for hospital admission related to COVID-19 in inflammatory rheumatic diseases
10 auth.
D. Freites,
L. León,
A. Mucientes,
L. Rodríguez-Rodríguez,
J. Font,
A. Madrid,
...
J. I. Colomer,
J. Jover,
B. Fernández-Gutiérrez,
L. Abasolo
|
3 |
2020 |
3
🐢
|
